27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next five years

July 18, 2017

Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis presented today at the Alzheimer's Association International Conference (AAIC) by ResearchersAgainstAlzheimer's (RA2), an UsAgainstAlzheimer's network.

"The Alzheimer's disease pipeline, marred by decades of failures and underinvestment, is due for big victories," said George Vradenburg, UsAgainstAlzheimer's Co-Founder and Chairman. "Thanks to growing investment from industry leaders, we remain cautiously optimistic that the current crop of late-stage Alzheimer's innovations will bring much-needed solutions to families in the near future."

The pipeline offers projections for drugs currently in Phase II and Phase III and identifies critical milestones in drug development, including estimated trial completion, estimated regulatory filing and estimated launch date. The analysis also provides a breakdown of the various mechanisms of action that are being tested to combat the progression of the disease. There are currently 23 drugs in Phase II and III targeting amyloid protein buildup in the brain, while 28 drugs are targeting neurotransmitter activity.

A novel treatment for Alzheimer's hasn't received FDA approval since 2003 and regulatory approval in Europe since 2002. However, the RA2 analysis confirms significant momentum by industry to forge ahead with Alzheimer's disease innovation. According to the analysis, there has been an 18-percent increase in Phase II drugs (49 to 58) and a 7-percent increase in Phase III drugs (30 to 32) in development from 2016 to 2017.

"There is no silver bullet when it comes to treating Alzheimer's," said Dr. David Morgan, a founding member of RA2 and a distinguished professor of Molecular Pharmacology and Physiology at the University of South Florida. "The more we learn about the underlying Alzheimer's pathology, the closer we get to a cure for a disease that is an enormous burden on patients, caregivers and global health systems."

A recent report by the Centers for Disease Control and Prevention found that Alzheimer's deaths have increased by 55 percent during a recent 15-year period (1999-2014). The late-stage Alzheimer's pipeline provides much-needed hope to the 5.5 million Americans with Alzheimer's and their caregivers who are desperate for a treatment or cure.

According to the analysis, six drugs will conclude Phase III trials in 2017. UsAgainstAlzheimer's and ResearchersAgainstAlzheimer's will continue actively tracking the progress of each drug and working across sectors to ensure that clinical trials are efficient and diverse, and that regulatory approaches to approving Alzheimer's drugs are modernized.

As new, potentially life-changing treatments inch closer to regulatory approval, the analysis, a semi-annual snapshot of the state of the Alzheimer's pipeline, begs the question: is the global health care system prepared to ensure that people with or at risk of Alzheimer's have access to the latest innovations once they reach the market?

"Alzheimer's is commonly misdiagnosed, and the United States suffers from a shortage of geriatricians - issues that will only grow as the Baby Boomer generation ages," Vradenburg said. "Private- and public-sector leaders will need to work closely with insurers in the coming years to ensure patients have access to these drugs when they are available."

Explore further: US deaths from Alzheimer's soar 55 percent since 1999

More information: To view RA2's AAIC poster presentation and read the full analysis, click here.

Related Stories

US deaths from Alzheimer's soar 55 percent since 1999

May 25, 2017
Deaths from Alzheimer's in America have soared 55 percent since 1999, as the burden of this fatal form of dementia grows and the population ages, a federal health report said Thursday.

Researchers identify urgent need for Alzheimer's drug development

July 3, 2014
Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering ...

Five million american seniors now living with alzheimer's

March 8, 2017
(HealthDay)—Alzheimer's disease claims nearly twice as many American lives annually as it did just 15 years ago, according to the 2017 Alzheimer's Disease Facts and Figures report, published March 7 by the Alzheimer's Association.

Promising drug trials for spin-out company in the fight against Alzheimer's disease

July 28, 2016
Phase three trials for a drug which targets Alzheimer's disease developed by a company spun out of the University of Aberdeen have shown promising results.

More than half of persons with Alzheimer's disease aged 90 years or more use psychotropic drugs

October 3, 2016
Psychotropic drug use is rather common among persons aged 90 years or more diagnosed with Alzheimer's disease, compared with those who were diagnosed at younger age, concludes a study conducted at the University of Eastern ...

Rules must evolve to allow new drugs for early Alzheimer's

March 14, 2013
(HealthDay)—Given the shift in the focus of drug development for Alzheimer's disease toward earlier disease stages, before the onset of dementia, regulatory guidelines need to evolve, according to a perspective piece published ...

Recommended for you

New mechanism detected in Alzheimer's disease

October 13, 2017
McGill University researchers have discovered a cellular mechanism that may contribute to the breakdown of communication between neurons in Alzheimer's disease.

Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer's disease

October 13, 2017
Microglia, immune cells that act as the central nervous system's damage sensors, have recently been implicated in Alzheimer's disease.

Green tea extract delivers molecular punch to disrupt formation of neurotoxic species

October 11, 2017
Green tea is widely considered to be beneficial for the brain. The antioxidant and detoxifying properties of green tea extracts help fight catastrophic diseases such as Alzheimer's. However, scientists have never fully understood ...

Menopause triggers metabolic changes in brain that may promote Alzheimer's

October 10, 2017
Menopause causes metabolic changes in the brain that may increase the risk of Alzheimer's disease, a team from Weill Cornell Medicine and the University of Arizona Health Sciences has shown in new research.

Being unaware of memory loss predicts Alzheimer's disease, new study shows

October 10, 2017
While memory loss is an early symptom of Alzheimer's disease, its presence doesn't mean a person will develop dementia. A new study at the Centre for Addiction and Mental Health (CAMH) has found a clinically useful way to ...

Alzheimer's gene poses both risk and benefits

October 9, 2017
Scientists drilling down to the molecular roots of Alzheimer's disease have encountered a good news/bad news scenario. A major player is a gene called TREM2, mutations of which can substantially raise a person's risk of the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.